Pyridostigmine Protects Against Diabetic Cardiomyopathy by Regulating Vagal Activity, Gut Microbiota, and Branched-Chain Amino Acid Catabolism in Diabetic Mice
The disruption of gut microbes is associated with diabetic cardiomyopathy, but the mechanism by which gut microbes affect cardiac damage remains unclear. We explored gut microbes and branched-chain amino acid (BCAA) metabolite catabolism in diabetic cardiomyopathy mice and investigated the cardiopro...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.647481/full |
| _version_ | 1818455431297630208 |
|---|---|
| author | Yang Yang Ming Zhao Xi He Qing Wu Dong-Ling Li Wei-Jin Zang |
| author_facet | Yang Yang Ming Zhao Xi He Qing Wu Dong-Ling Li Wei-Jin Zang |
| author_sort | Yang Yang |
| collection | DOAJ |
| description | The disruption of gut microbes is associated with diabetic cardiomyopathy, but the mechanism by which gut microbes affect cardiac damage remains unclear. We explored gut microbes and branched-chain amino acid (BCAA) metabolite catabolism in diabetic cardiomyopathy mice and investigated the cardioprotective effect of pyridostigmine. The experiments were conducted using a model of diabetic cardiomyopathy induced by a high-fat diet + streptozotocin in C57BL/6 mice. The results of high-throughput sequencing showed that diabetic cardiomyopathy mice exhibited decreased gut microbial diversity, altered abundance of the diabetes-related microbes, and increased abundance of the BCAA-producing microbes Clostridiales and Lachnospiraceae. In addition, diabetes downregulated tight junction proteins (ZO-1, occludin, and claudin-1) and increased intestinal permeability to impair the intestinal barrier. These impairments were accompanied by reduction in vagal activity that manifested as increased acetylcholinesterase levels, decreased acetylcholine levels, and heart rate variability, which eventually led to cardiac damage. Pyridostigmine enhanced vagal activity, restored gut microbiota homeostasis, decreased BCAA-producing microbe abundance, and improved the intestinal barrier to reduce circulating BCAA levels. Pyridostigmine also upregulated BCAT2 and PP2Cm and downregulated p-BCKDHA/BCKDHA and BCKDK to improve cardiac BCAA catabolism. Moreover, pyridostigmine alleviated abnormal mitochondrial structure; increased ATP production; decreased reactive oxygen species and mitochondria-related apoptosis; and attenuated cardiac dysfunction, hypertrophy, and fibrosis in diabetic cardiomyopathy mice. In conclusion, the gut microbiota, BCAA catabolism, and vagal activity were impaired in diabetic cardiomyopathy mice but were improved by pyridostigmine. These results provide novel insights for the development of a therapeutic strategy for diabetes-induced cardiac damage that targets gut microbes and BCAA catabolism. |
| first_indexed | 2024-12-14T22:10:40Z |
| format | Article |
| id | doaj.art-4eb37ac029fd458586a27148a4c3cb84 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-14T22:10:40Z |
| publishDate | 2021-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-4eb37ac029fd458586a27148a4c3cb842022-12-21T22:45:45ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-05-011210.3389/fphar.2021.647481647481Pyridostigmine Protects Against Diabetic Cardiomyopathy by Regulating Vagal Activity, Gut Microbiota, and Branched-Chain Amino Acid Catabolism in Diabetic MiceYang YangMing ZhaoXi HeQing WuDong-Ling LiWei-Jin ZangThe disruption of gut microbes is associated with diabetic cardiomyopathy, but the mechanism by which gut microbes affect cardiac damage remains unclear. We explored gut microbes and branched-chain amino acid (BCAA) metabolite catabolism in diabetic cardiomyopathy mice and investigated the cardioprotective effect of pyridostigmine. The experiments were conducted using a model of diabetic cardiomyopathy induced by a high-fat diet + streptozotocin in C57BL/6 mice. The results of high-throughput sequencing showed that diabetic cardiomyopathy mice exhibited decreased gut microbial diversity, altered abundance of the diabetes-related microbes, and increased abundance of the BCAA-producing microbes Clostridiales and Lachnospiraceae. In addition, diabetes downregulated tight junction proteins (ZO-1, occludin, and claudin-1) and increased intestinal permeability to impair the intestinal barrier. These impairments were accompanied by reduction in vagal activity that manifested as increased acetylcholinesterase levels, decreased acetylcholine levels, and heart rate variability, which eventually led to cardiac damage. Pyridostigmine enhanced vagal activity, restored gut microbiota homeostasis, decreased BCAA-producing microbe abundance, and improved the intestinal barrier to reduce circulating BCAA levels. Pyridostigmine also upregulated BCAT2 and PP2Cm and downregulated p-BCKDHA/BCKDHA and BCKDK to improve cardiac BCAA catabolism. Moreover, pyridostigmine alleviated abnormal mitochondrial structure; increased ATP production; decreased reactive oxygen species and mitochondria-related apoptosis; and attenuated cardiac dysfunction, hypertrophy, and fibrosis in diabetic cardiomyopathy mice. In conclusion, the gut microbiota, BCAA catabolism, and vagal activity were impaired in diabetic cardiomyopathy mice but were improved by pyridostigmine. These results provide novel insights for the development of a therapeutic strategy for diabetes-induced cardiac damage that targets gut microbes and BCAA catabolism.https://www.frontiersin.org/articles/10.3389/fphar.2021.647481/fulldiabetic cardiomyopathygut microbiotabranched-chain amino acidspyridostigminemitochondrial dysfunctionvagal activity |
| spellingShingle | Yang Yang Ming Zhao Xi He Qing Wu Dong-Ling Li Wei-Jin Zang Pyridostigmine Protects Against Diabetic Cardiomyopathy by Regulating Vagal Activity, Gut Microbiota, and Branched-Chain Amino Acid Catabolism in Diabetic Mice Frontiers in Pharmacology diabetic cardiomyopathy gut microbiota branched-chain amino acids pyridostigmine mitochondrial dysfunction vagal activity |
| title | Pyridostigmine Protects Against Diabetic Cardiomyopathy by Regulating Vagal Activity, Gut Microbiota, and Branched-Chain Amino Acid Catabolism in Diabetic Mice |
| title_full | Pyridostigmine Protects Against Diabetic Cardiomyopathy by Regulating Vagal Activity, Gut Microbiota, and Branched-Chain Amino Acid Catabolism in Diabetic Mice |
| title_fullStr | Pyridostigmine Protects Against Diabetic Cardiomyopathy by Regulating Vagal Activity, Gut Microbiota, and Branched-Chain Amino Acid Catabolism in Diabetic Mice |
| title_full_unstemmed | Pyridostigmine Protects Against Diabetic Cardiomyopathy by Regulating Vagal Activity, Gut Microbiota, and Branched-Chain Amino Acid Catabolism in Diabetic Mice |
| title_short | Pyridostigmine Protects Against Diabetic Cardiomyopathy by Regulating Vagal Activity, Gut Microbiota, and Branched-Chain Amino Acid Catabolism in Diabetic Mice |
| title_sort | pyridostigmine protects against diabetic cardiomyopathy by regulating vagal activity gut microbiota and branched chain amino acid catabolism in diabetic mice |
| topic | diabetic cardiomyopathy gut microbiota branched-chain amino acids pyridostigmine mitochondrial dysfunction vagal activity |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.647481/full |
| work_keys_str_mv | AT yangyang pyridostigmineprotectsagainstdiabeticcardiomyopathybyregulatingvagalactivitygutmicrobiotaandbranchedchainaminoacidcatabolismindiabeticmice AT mingzhao pyridostigmineprotectsagainstdiabeticcardiomyopathybyregulatingvagalactivitygutmicrobiotaandbranchedchainaminoacidcatabolismindiabeticmice AT xihe pyridostigmineprotectsagainstdiabeticcardiomyopathybyregulatingvagalactivitygutmicrobiotaandbranchedchainaminoacidcatabolismindiabeticmice AT qingwu pyridostigmineprotectsagainstdiabeticcardiomyopathybyregulatingvagalactivitygutmicrobiotaandbranchedchainaminoacidcatabolismindiabeticmice AT donglingli pyridostigmineprotectsagainstdiabeticcardiomyopathybyregulatingvagalactivitygutmicrobiotaandbranchedchainaminoacidcatabolismindiabeticmice AT weijinzang pyridostigmineprotectsagainstdiabeticcardiomyopathybyregulatingvagalactivitygutmicrobiotaandbranchedchainaminoacidcatabolismindiabeticmice |